A carregar...
Targeting the “PVR–TIGIT axis” with immune checkpoint therapies
Checkpoint inhibitors have become an efficient way to treat cancers. Indeed, anti-CTLA-4, anti-PD1, and anti-PDL-1 antibodies are now used as therapies for cancers. However, while these therapies are very efficient in certain tumors, they remain poorly efficient in others. This might be explained by...
Na minha lista:
| Publicado no: | F1000Res |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
F1000 Research Limited
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7222031/ https://ncbi.nlm.nih.gov/pubmed/32489646 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12688/f1000research.22877.1 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|